Valeant Pharma (VRX) Reports Q1 EPS of $1.30; Boosts FY13 EPS Outlook

May 2, 2013 6:28 AM

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) reported Q1 EPS of $1.30, versus $0.91 reported ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found